Compare TNL & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNL | MIRM |
|---|---|---|
| Founded | 1990 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 4.2B |
| IPO Year | N/A | 2019 |
| Metric | TNL | MIRM |
|---|---|---|
| Price | $69.51 | $102.29 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 11 |
| Target Price | $72.00 | ★ $100.09 |
| AVG Volume (30 Days) | 568.3K | ★ 814.2K |
| Earning Date | 02-18-2026 | 02-25-2026 |
| Dividend Yield | ★ 3.19% | N/A |
| EPS Growth | ★ 3.11 | N/A |
| EPS | ★ 6.07 | N/A |
| Revenue | ★ $3,967,000,000.00 | $471,794,000.00 |
| Revenue This Year | $4.45 | $54.98 |
| Revenue Next Year | $4.34 | $21.94 |
| P/E Ratio | $11.57 | ★ N/A |
| Revenue Growth | 3.60 | ★ 53.66 |
| 52 Week Low | $37.77 | $36.88 |
| 52 Week High | $76.21 | $103.81 |
| Indicator | TNL | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 43.87 | 77.89 |
| Support Level | $68.76 | $89.47 |
| Resistance Level | $70.43 | $103.81 |
| Average True Range (ATR) | 1.77 | 4.05 |
| MACD | -0.54 | 0.79 |
| Stochastic Oscillator | 14.94 | 92.80 |
Travel+Leisure Co is a membership and leisure travel company. It provides hospitality services and travel products. The company operates in the segments of Vacation Ownership, which is the key revenue-driving segment, develops, markets and sells vacation ownership interests (VOIs) to individual consumers, provides consumer financing in connection with the sale of VOIs, and provides property management services at resorts, and Travel and Membership which operates a variety of travel businesses, including three vacation exchange brands, a home exchange network, travel technology platforms, travel memberships, and direct-to-consumer rentals. The majority of the revenue is earned from the United States.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.